
ReproCELL Incorporated — Investor Relations & Filings
ReproCELL Incorporated is a global company providing solutions for preclinical and clinical research, with a primary focus on stem cell technology, drug discovery, and regenerative medicine. The company's portfolio includes a wide range of products such as induced pluripotent stem cells (iPSCs), differentiated cells, 3D cell culture models, and specialized reagents like RNA-based reprogramming kits that avoid genomic integration. ReproCELL also offers extensive contract research services, including human tissue assays for evaluating drug efficacy and safety. A key area of expertise is the GMP-compliant manufacturing of clinical-grade iPSCs and iPSC-derived mesenchymal stem cells (iMSCs), supporting the development of advanced cell therapies. The company's tools and services are designed to help academic and commercial scientists accelerate the translation of research into clinical applications.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 連結子会社(REPROCELL USA Inc.)に対する補助金の交付決定に関するお知らせ | 2026-05-22 | Japanese | |
| 確認書 | 2025-11-13 | Japanese | |
| 半期報告書-第24期(2025/04/01-2026/03/31) | 2025-11-13 | Japanese | |
| 内部統制報告書-第23期(2024/04/01-2025/03/31) | 2025-06-26 | Japanese | |
| 確認書 | 2025-06-26 | Japanese | |
| 有価証券報告書-第23期(2024/04/01-2025/03/31) | 2025-06-26 | Japanese |
Browse filings by year
12 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
1 filing
| |||||
| 46779402 | 連結子会社(REPROCELL USA Inc.)に対する補助金の交付決定に関するお知らせ | 2026-05-22 | Japanese | ||
|
2025
5 filings
| |||||
| 8284113 | 確認書 | 2025-11-13 | Japanese | ||
| 8284101 | 半期報告書-第24期(2025/04/01-2026/03/31) | 2025-11-13 | Japanese | ||
| 7246941 | 内部統制報告書-第23期(2024/04/01-2025/03/31) | 2025-06-26 | Japanese | ||
| 7246936 | 確認書 | 2025-06-26 | Japanese | ||
| 7246939 | 有価証券報告書-第23期(2024/04/01-2025/03/31) | 2025-06-26 | Japanese | ||
|
2024
9 filings
| |||||
| 7298959 | 確認書 | 2024-11-13 | Japanese | ||
| 7298954 | 半期報告書-第23期(2024/04/01-2025/03/31) | 2024-11-13 | Japanese | ||
| 7325542 | 臨時報告書 | 2024-06-26 | Japanese | ||
| 7328563 | 内部統制報告書-第22期(2023/04/01-2024/03/31) | 2024-06-25 | Japanese | ||
| 7328560 | 確認書 | 2024-06-25 | Japanese | ||
| 7328561 | 有価証券報告書-第22期(2023/04/01-2024/03/31) | 2024-06-25 | Japanese | ||
| 7336087 | 臨時報告書 | 2024-05-23 | Japanese | ||
| 7356961 | 確認書 | 2024-02-09 | Japanese | ||
| 7356958 | 四半期報告書-第22期第3四半期(2023/10/01-2023/12/31) | 2024-02-09 | Japanese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Alpha Tau Medical Ltd.
Clinical-stage oncology firm developing alpha radiation the…
|
DRTS | US | Professional, scientific and te… |
|
Alteogen Inc.
Biopharmaceutical firm developing biologics with proprietar…
|
196170 | KR | Professional, scientific and te… |
|
ALTERITY THERAPEUTICS LIMITED
Clinical-stage developer of disease-modifying therapies for…
|
ATH | AU | Professional, scientific and te… |
|
AlzeCure Pharma
Develops therapies for severe diseases, focusing on Alzheim…
|
ALZCUR | SE | Professional, scientific and te… |
|
AMPLIA THERAPEUTICS LIMITED
Clinical-stage developer of FAK inhibitors for solid tumors…
|
ATX | AU | Professional, scientific and te… |
|
ANAPTYSBIO, INC
Clinical-stage biotech developing immunology therapeutics f…
|
ANAB | US | Professional, scientific and te… |
|
ANATARA LIFESCIENCES LTD
Develops non-antibiotic gastrointestinal health solutions f…
|
ANR | AU | Professional, scientific and te… |
|
AngioLab, Inc.
Develops angiogenesis inhibitors for pharmaceuticals and he…
|
251280 | KR | Professional, scientific and te… |
|
Anhui Wanbang Pharmaceutical Technology Co.,Ltd.
Pharmaceutical CRO specializing in clinical trials, BE stud…
|
301520 | CN | Professional, scientific and te… |
|
Anixa Biosciences Inc
A clinical-stage biotech developing therapies and vaccines …
|
ANIX | US | Professional, scientific and te… |
ReproCELL Incorporated via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/13724/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=13724 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=13724 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=13724 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 13724}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for ReproCELL Incorporated (id: 13724)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.